Mundipharma names Philippe Mazas as new Chief Information Officer

pharmafile | December 4, 2017 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Mundipharma, Philippe Mazas 

Mundipharma has announced that it has appointed Philippe Mazas as its new Chief Information Officer (CIO).

Mazas boasts nearly 20 years of experience in the role across a number of industries, including the automotive sector where he began his career with Renault Group. He served as Regional CIO for South America at the company before taking on the role of Information Officer for General Motors Europe. Mazas worked most recently as CIO at Smith & Nephew, a FTSE 100 global medical technology company.

In his new role, Mazas will be responsible for IT services provided to Mundipharma’s network of independent associated companies.

Commenting on his appointment, Mazas said: “Taking an entrepreneurial approach to technology is vital for pharma companies that want to stay ahead of the ever advancing pace of digital transformation. My goal is to ensure that the Mundipharma network has the technology support it needs to lead the charge in pharma by being customer focused, value driven and business led.   This approach will enable us to be more efficient and nimble, while ensuring the Mundipharma network continues to advance technology to aid in the development and commercialisation of medicines that address patients’ needs.”

 

Related Content

european_commission_web

Europe extends Invokana indication to cover diabetic kidney disease in type 2 diabetes patients

European Commission has moved to expand the existing approved indication for Mundipharma’s Invokana (canagliflozin), making …

920x920

Pharma firms paid Italian doctor to promote opioid drugs

Opioid drugmakers paid an Italian pain doctor to promote opioid painkillers as a treatment for …

top_10_image

Top Ten most popular articles on Pharmafile.com this week!

Some big names – including Gilead, Janssen, Teva and Bristol-Myers Squibb – were in trouble …

Latest content